已发表论文

TGFB1  T869C多态性对非小细胞肺癌 (NSCLC) 的不良预后影响

 

Authors Sang Y, Bi X, Liu Y, Zhang W, Wang D

Received 1 October 2016

Accepted for publication 9 November 2016

Published 10 March 2017 Volume 2017:10 Pages 1513—1518

DOI https://doi.org/10.2147/OTT.S123685

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 2

Editor who approved publication: Dr Carlos Vigil Gonzales

Abstract: Previously, several polymorphisms in TGFB1  have been identified in non-small-cell lung cancer (NSCLC), and the variants, C-509T, T869C, and G915C, have been demonstrated to associate with higher circulating levels of TGF-β1. However, little is known about the prognostic value of TGF-β1 polymorphisms in cancers. In this study, by genotyping the TGF-β1 T869C polymorphism in a total of 261 patients with NSCLC using DNA from blood lymphocytes, we first found that NSCLC patients, especially those with allele C carriers, had significantly higher serum TGF-β1 levels than healthy individuals. By using chi-square (χ 2) test and Fisher’s exact test, we noticed that TC/CC genotypes were positively correlated with smoking, clinical TNM stage, lymph node, and distant metastasis in NSCLC patients. Kaplan–Meier analysis showed that patients with TT genotype had a better overall survival than the allele C carriers (TC + CC). Finally, multivariate analysis confirmed histology, lymph node, and distant metastasis but not T869C polymorphism as independent prognostic factors for NSCLC. Taken together, our data, as a proof of principle, suggest that T869C polymorphism in TGFB1  may act as a genetic modifier in NSCLC progression and a promising prognostic marker of survival in NSCLC patients.
Keywords: genotype and multivariate analysis, single-nucleotide polymorphisms, prognosis